Viromed Medical AG (XTER:VME) Marketable Securities: €0.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:VME Viromed Medical AG XTER:VME
22 GF Score
Price €7.45
! 5 Warning Signs
View Full Analysis

What is Viromed Medical AG Marketable Securities?

Viromed Medical AG XTER:VME 22 Marketable Securities is €0.01 Mil as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Viromed Medical AG's Marketable Securities for the quarter that ended in Dec. 2025 was €0.01 Mil.

Viromed Medical AG's annual Marketable Securities increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.01 Mil).

Viromed Medical AG  (XTER:VME) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Viromed Medical AG Marketable Securities Related Terms

Viromed Medical AG Marketable Securities Historical Data

* Premium members only.

The historical data trend for Viromed Medical AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viromed Medical AG Marketable Securities Chart

Viromed Medical AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.00 0.00 0.01

Viromed Medical AG Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.01
XTER:VME
22GF Score
Viromed Medical AG XTER:VME
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viromed Medical AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.01 Mil mean?
Viromed Medical AG (XTER:VME) has a Marketable Securities of €0.01 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Viromed Medical AG and its competitors.
Is Viromed Medical AG's Marketable Securities too high?
Viromed Medical AG's current Marketable Securities is €0.01 Mil. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's Marketable Securities compare to ABT and SYK?
Viromed Medical AG's Marketable Securities of €0.01 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Viromed Medical AG and its competitors. Viromed Medical AG's current Marketable Securities is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current Marketable Securities of €0.01 Mil. The current Marketable Securities is €0.01 Mil. Viromed Medical AG's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current Marketable Securities is €0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viromed Medical AG Business Description

Other Exchanges VME:GermanyVME:Germany
Address Hauptstrasse 105, Rellingen, Pinneberg, SH, DEU, 25462
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score

Get the complete analysis for XTER:VME

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.45
Price